8-K: Catalyst Crew Technologies Acquires AI Healthcare Platform Assets

Catalyst Crew Technologies Corp. has acquired intellectual property for an AI-enabled healthcare analytics platform from its CEO, Kevin Rodan Levy, and established a Venezuelan subsidiary for its Latin American strategy.

Summary

• Catalyst Crew Technologies Corp. entered into an Asset Purchase Agreement (APA) on February 17, 2026, with its CEO, Kevin Rodan Levy, to acquire assets including intellectual property for an AI-enabled healthcare analytics platform.
• The acquisition closed around February 20, 2026, and included proprietary software, machine learning models, datasets, and patent registrations in Venezuela for CardioAI, PulmoAI, and NeuroAI technologies.
• On March 23, 2026, the company acquired 100% of Inversiones Long 33, C.A., a Venezuelan corporation, through a Share Assignment Agreement with the seller.
• This subsidiary is intended to be the company's operating entity in Venezuela and part of its Latin American strategy.
• On April 7, 2026, certain intellectual property acquired via the APA was formally assigned to the subsidiary, Inversiones Long 33, C.A., as an internal reorganization step.
• The company issued several press releases between March 23 and April 13, 2026, announcing the establishment of its operating structure, IP assignment, and the introduction of its AI healthcare platforms.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing corporate restructuring and asset acquisition without providing financial performance metrics or forward-looking guidance.

Positives

• Acquisition of intellectual property for an AI-enabled healthcare analytics platform, including CardioAI, PulmoAI, and NeuroAI technologies.
• Establishment of a wholly-owned subsidiary in Venezuela to serve as an operating entity and support Latin American strategy.
• Formal assignment of intellectual property to the Venezuelan subsidiary, aligning the company's operating structure.
• Public dissemination of key developments through press releases, enhancing transparency.

Risks

• The filing does not detail the specific financial terms or consideration paid for the asset purchase or the subsidiary acquisition, making it difficult to assess the financial impact.
• The intellectual property is registered in Venezuela, which may present jurisdictional or operational risks.
• The effectiveness and market adoption of the AI-enabled healthcare analytics platforms are not detailed, posing a risk to future revenue generation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance or strategic objectives beyond the establishment of the Venezuelan operating structure and the introduction of AI platforms.

Management Comments

• The assignment of intellectual property to the Subsidiary was an internal reorganization step intended to align the Company's operating structure in Venezuela.
• The Subsidiary was previously formed and is intended to serve as the Company's operating entity in Venezuela and as part of its broader Latin American strategy.

Industry Context

StockSavvy.ai notes that the acquisition of AI-enabled healthcare analytics platforms aligns with a significant trend in the healthcare technology sector, where companies are increasingly leveraging artificial intelligence to improve diagnostics, patient outcomes, and operational efficiency. Competitors are also investing heavily in similar technologies.

Related Party Transactions

• Asset Purchase Agreement with CEO Kevin Rodan Levy for AI healthcare analytics platform assets.
• Share Assignment Agreement with CEO Kevin Rodan Levy for the acquisition of Inversiones Long 33, C.A.
• Intellectual Property Assignment Agreement between CEO Kevin Rodan Levy and the subsidiary Inversiones Long 33, C.A.

Stakeholder Impact

• Shareholders: Potential long-term value creation from the acquired AI healthcare technology, but no immediate financial impact is detailed.
• Employees: Potential for new roles and opportunities related to AI healthcare analytics and Latin American operations.
• Management: Direct involvement of CEO Kevin Rodan Levy in both the sale of assets and the subsequent assignment to the subsidiary.

Next Steps

• Integration of acquired AI healthcare analytics platform assets into the company's operations.
• Development and execution of the company's broader Latin American strategy, utilizing the Venezuelan subsidiary.

Key Dates

Keywords

Catalyst Crew Technologies, Form 8-K, Asset Purchase Agreement, AI Healthcare Analytics, CardioAI, PulmoAI, NeuroAI, Inversiones Long 33, C.A.